Treatment of Concurrent Minimal Change Disease and Epstein Barr Virus–Driven Post-transplant Lymphoproliferative Disorder With Rituximab Following Hematopoietic Stem Cell Transplantation

समान संसाधन

• Rituximab-Induced Remission in Epstein−Barr Virus−Associated Glomerulonephritis
  द्वारा: Alabdaljabar, Mohamad S., और अन्य
  प्रकाशित: (2020)
• Endobronchial Epstein-Barr Virus Associated Post-transplant Lymphoproliferative Disorder in Hematopoietic Stem Cell Transplantation
  द्वारा: Feuillet, S., और अन्य
  प्रकाशित: (2009)
• Management of Epstein–Barr virus-related post-transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation
  द्वारा: Liu, Li, और अन्य
  प्रकाशित: (2020)
• A Case of Epstein-Barr Virus–Associated Leiomyosarcoma Concurrently With Posttransplant Lymphoproliferative Disorders After Renal Transplantation
  द्वारा: Aida, Naohiro, और अन्य
  प्रकाशित: (2019)
• Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation
  द्वारा: Uhlin, Michael, और अन्य
  प्रकाशित: (2014)